CMR Surgical has raised $600m (£425m) in a Series D funding round to boost the commercialisation of its Versius surgical robotic system globally.
SoftBank Vision Fund 2 co-led the financing round with Ally Bridge Group.
The funding was also supported by new investors, including RPMI Railpen, Tencent and Chimera, with participation from Cambridge Innovation Capital, PFM Health Sciences and GE Healthcare, among others.
Apart from enhancing access to keyhole surgery, the company will use the proceeds to continue the development of its digital ecosystem, including technological advancements to an app for surgeons who use the Versius system.
CMR Surgical collaborates with surgeons and hospitals to offer an accessible and cost-effective solution for robotic keyhole surgery.
Versius is a portable system that can suit virtually any operating room set-up and integrates easily into current workflows.
Biomimicking the human arm, Versius allows optimised port placement as well as precision of small fully-wristed instruments.
The robotic device also features 3D HD vision, instrument control and various working positions. It is intended to lower stress and fatigue for surgeons as well as facilitate communication with the team.
In addition, Versius gathers data using its digital ecosystem to aid in improving surgical care. The system offers insights via the Versius Connect app, Versius Trainer and CMR clinical registry.
CMR Surgical launched the surgical robotic system in several markets, including Europe, Australia, India and the Middle East, as part of its ongoing international expansion.
The company will leverage the Series D funding to fast-track its expansion. It also expects an increase in demand for Versius globally.
CMR Surgical CEO Per Vegard Nerseth said: “This latest financing equips CMR with significant funds to accelerate our mission of bringing Versius to hospitals worldwide, whilst providing full flexibility to achieve our goals.
“As the lead investor, SoftBank has a wealth of experience supporting disruptive business models and innovative technologies, and we look forward to leveraging their expertise and extensive ecosystem.”
The latest funding values the company at $3bn.